Zevra Therapeutics has been granted a patent for a crystalline form of emetine dihydrochloride, with potential applications in manufacturing processes and methods of use. GlobalData’s report on Zevra Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Zevra Therapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Zevra Therapeutics, Nanoparticle drug conjugates was a key innovation area identified from patents. Zevra Therapeutics's grant share as of February 2024 was 44%. Grant share is based on the ratio of number of grants to total number of patents.

Crystalline form of emetine dihydrochloride

Source: United States Patent and Trademark Office (USPTO). Credit: Zevra Therapeutics Inc

A recently granted patent (Publication Number: US11884663B2) discloses a crystalline form of Compound I dihydrochloride, characterized by specific X-ray powder diffractograms. The patent claims various forms of the crystalline compound, each with distinct peaks in their diffractograms, such as Form 2, Form 4, Form 5, and Form 6. Additionally, the patent covers pharmaceutical compositions containing the crystalline form of Compound I dihydrochloride along with a pharmaceutically acceptable carrier, and optionally, other therapeutic agents like antiparasitic agents, antibiotics, antiviral agents, or agents for controlling a cytokine storm.

Furthermore, the patent outlines methods for treating viral infections, including Flavivirus infections, Zika virus, Ebola virus, coronaviruses (such as SARS-COV-2 causing COVID-19), and other viral diseases. The methods involve administering the crystalline form of Compound I dihydrochloride to the subject in need of treatment. Notably, the patent specifies that in the case of SARS-COV-2 infections, the subject does not require hospitalization, and severe symptoms of Cytokine Release Syndrome (cytokine storm) are not exhibited. This patent provides a comprehensive framework for utilizing the crystalline form of Compound I dihydrochloride in treating a range of viral infections and diseases, offering potential therapeutic benefits in various clinical settings.

To know more about GlobalData’s detailed insights on Zevra Therapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies